Navigation Links
Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress

BASEL, Switzerland, May 21, 2007 - Results from phase III clinical trials and further human pharmacology studies were presented at the 16th Congress of the European Academy of Dermatology and Venereology (EADV). These data highlighted the efficacy and safety profile of alitretinoin as a potential once daily oral treatment for patients with severe refractory chronic hand eczema.

Currently, no approved treatment exists for severe Chronic Hand Eczema (CHE) refractory or unresponsive to topical therapy. This debilitating disease can cause significant pain and functional impairment of the hands as well as considerable psychological, social and occupational impact on patients' lives. The data presented at this meeting will form part of the regulatory submissions later this year and show the potential for alitretinoin to become the first product available to treat an estimated one million patients in North America and Europe.

Eight posters on alitretinoin presented in the main conference and four oral presentations in a company sponsored satellite symposium highlighted alitretinoin as a potential treatment for severe refractory CHE.

Positive efficacy and safety data on alitretinoin were reported in posters from the pivotal BACH trial (poster number 275), the re-treatment study (280) and an open-label safety study (281). Five further posters covered aspects of the pharmacology of alitretinoin (286, 287, 288, 289 and 290).

Previously reported results for the phase III BACH study (275) confirm the efficacy and tolerability of oral alitretinoin for the treatment of CHE in patients refractory to topical corticosteroids. Once daily alitretinoin resulted in response of 48% of the patients who were treated with 30mg per day for up to six months. Response rate and time to response were dose dependent with a faster response seen with the higher dose. Alitretinoin was generally well tolerated in these clinical studies with an adverse event profile typical of the retinoid drug class.

Patients with CHE often relapse, however, approximately 70% of patients treated with alitretinoin in the BACH trial remained relapse free, as defined in the protocol, during a six month post-treatment observation period without any form of maintenance treatment.

Basilea's re-treatment study (280) demonstrated that those patients with disease recurrence remained responsive to another course of alitretinoin treatment with a response rate of 80% in the 30mg group. The primary and secondary efficacy endpoints were consistent with previously reported primary treatment studies and repeated treatment courses of alitretinoin were generally well tolerated.

An open-label study (281) provided further safety data confirming that in patients with severe refractory CHE, exposure to alitretinoin 30mg beyond six months is well tolerated.

Summary of Poster Presentations

P275 / Efficacy and safety of alitretinoin in severe refractory chronic hand eczema. Ruzicka T, Gupta A, Jemec G, Gerlach B, Maares J, Wevelsiep L.

P280 / Re-treatment study of alitretinoin (9-cis retinoic acid) in severe chronic hand eczema refractory to topical treatment. Ruzicka T, Lahfa M, Lynde Ch, Coenraads PJ, Harsch M, Maares J.

P281 / An open label study of the safety and efficacy of alitretinoin in severe refractory chronic hand eczema. Diepgen T, Maleszka R, Bissonnette R, Augustin M, Harsch M, Brown T.

P286 / Alitretinoin (BAL4079; 9-cis retinoic acid): Pharmacokinetic interactions between aitretinoin, ketoconazole, simvastatin and cyclosporine A. Schmitt-Hoffmann A, Roos B, Baumgaertner E, Maares J.

P287 / Alitretinoin (BAL4079; 9-cis retinoic acid): Pharmacokinetics after single and repeated oral dosing of 20 and 40mg in healthy volunteers. Schmitt-Hoffman A, Roos B, Brown T, Meyer I.

P288 / Alitretinoin (BAL4079; 9-cis retinoic acid): Pharmacokinetics after single and repeated oral dosing of 5, 10 and 20mg in healthy volunteers. Schmitt-Hoffman A, Roos B, Brown T, Maares J.

P289 / Alitretinoin (BAL4079; 9-cis retinoic acid): Mass-balance excretion study of oral alitretinoin in healthy volunteers. Schmitt-Hoffman A, Roos B, Brown T, van Lier JJ.

P290 / Alitretinoin (BAL4079: 9-cis retinoic acid): Low levels in seminal fluid after repeated oral dosing. Schmitt-Hoffman A, Roos B, Brown T, Meyer I.

About Chronic Hand Eczema (CHE) Hand eczema is a common skin disease and is often chronic and relapsing. It is estimated to affect up to 10% of the general population. The more severe, chronic form of the condition is thought to affect up to 7% of these patients, many of whom do not respond, or no longer respond to topical corticosteroids. Basilea estimates there are at least one million patients in Europe and North America with severe refractory CHE for which currently no approved, effective pharmaceutical treatment is available.

About Alitretinoin Alitretinoin is an investigational drug being developed in Phase III clinical trials by Basilea as a novel treatment for severe refractory Chronic Hand Eczema (CHE), a complex disease for which no effective treatment options are currently available. Alitretinoin has been shown to be effective in clinical studies in patients with severe refractory CHE. Alitretinoin is a teratogen and therefore pregnancy prevention measures must be in place for all women of child-bearing potential who receive alitretinoin. Within days after discontinuation of therapy, alitretinoin levels return to endogenous levels. In clinical studies the post-treatment contraceptive period was four weeks.

About Basilea Basilea Pharmaceutica Ltd. is an independent biopharmaceutical company headquartered in Basel, Switzerland, and listed on the SWX Swiss Exchange (SWX:BSLN). Basilea's fully integrated research and development operations are currently focused on new antibacteria l and antifungal agents to fight drug resistance and on the development of dermatology drugs. Basilea's products are targeted to satisfy high medical and patient needs in the hospital and specialty care setting. The company owns a diversified portfolio including three investigational phase III drugs of which two have shown positive pivotal phase III results. The company is integrating commercialization into its organization, in a first step through co-promoting ceftobiprole with its partner Cilag GmbH International, a Johnson & Johnson company, in North America and major European countries.

Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

+----------------------------------------------------------+ | General Information | Investor Relations | |-------------------------+--------------------------------| | | Dr. Barbara Zink | | | | +----------------------------------------------------------+

This press release can be downloaded from

The press release can also be downloaded from the fol lowing link:

This content was distributed through Hugin - connecting communication professionals/with their target audience. Visit us at

Unsubscribe at


Related medicine technology :

1. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
6. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
7. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
8. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
9. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
10. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
11. Studies Show Efficacy and Safety of Alexions Soliris in Broad Population of PNH Patients
Post Your Comments:
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):